Test Price
450 AEDโ Home Collection Available
P57 Immunohistochemistry Test in UAE | 450 AED | DHA-Licensed Molecular Pathology
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity for complete versus partial hydatidiform mole differentiation via ISO 9001:2015 accredited immunohistochemistry.
- Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval โ archival FFPE blocks or biopsy slides collected from hospital pathology departments.
- Post-Test Support: Telephonic result interpretation provided by a DHA-licensed specialist radiology professional.
- Insurance & Billing: Direct billing verification available via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The P57 Immunohistochemistry (IHC) Test is a specialised tissue-based assay that uses a monoclonal antibody directed against the p57 protein, a cyclin-dependent kinase inhibitor encoded by the CDKN1C gene. This assay is performed on formalin-fixed, paraffin-embedded (FFPE) tissue sections to evaluate nuclear p57 expression in villous cytotrophoblasts and stromal cells. Loss of p57 nuclear staining is a hallmark of complete hydatidiform mole, enabling definitive discrimination from partial hydatidiform mole and non-molar conceptions. The test is processed under ISO 9001:2015 quality management standards within our DHA-licensed laboratory at Dubai Healthcare City.
Comparative Diagnostic Utility
| Feature | P57 IHC Test | Standard Histopathology (H&E) |
|---|---|---|
| Methodology | Immunohistochemistry with monoclonal p57 antibody on FFPE tissue | Hematoxylin & Eosin morphological assessment |
| Diagnostic Precision | 99.9% sensitivity, high specificity for complete vs partial mole | ~85% accuracy; may miss subtle trophoblastic abnormalities |
| Turnaround Time | 5โ7 days from FFPE block receipt | 3โ5 days |
| Clinical Utility | Definitive differentiation; guides oncological follow-up | Screening only; often requires IHC for confirmation |
Physician Insight & Safety Protocols
โThe P57 IHC assay is a cornerstone of gestational trophoblastic disease classification. A negative nuclear stain in morphologically abnormal villous tissue provides robust evidence for complete mole diagnosis, which directly influences the patientโs surveillance regimen and chemotherapy risk assessment. However, this result must always be integrated with serial ฮฒ-hCG measurements, ultrasound findings, and the full clinical picture. Our team is committed to delivering precise, clearly communicated results to support your treatment decisions.โ
โ Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory Notice
Medication Continuity
Do not discontinue any prescribed medication without prior consultation with your treating physician. The P57 IHC test does not require alteration of ongoing therapies.
Exclusion Criteria & Emergency Red Flags
- Inadequate specimen: tissue not fixed in 10% neutral buffered formalin or insufficient volume for sectioning.
- Recent high-dose anticoagulant therapy that may increase biopsy-related bleeding risk (requires specialist clearance prior to any new tissue collection).
- Known hypersensitivity to formalin fixative (extremely rare).
- Seek emergency care immediately if you experience heavy vaginal bleeding, fever, or severe abdominal pain following a biopsy procedure.
Patient FAQ & Clinical Guidance
1. What is the P57 immunohistochemistry test used for?
Quick Answer: It is the gold-standard IHC marker for distinguishing complete hydatidiform mole from partial mole and non-molar pregnancies through nuclear p57 protein detection.
Absent p57 nuclear staining in villous cytotrophoblasts confirms a complete mole, while retained staining indicates a partial mole or benign conception. This classification directly determines the need for post-molar hCG surveillance and the risk of persistent gestational trophoblastic neoplasia.
2. How should I prepare for the P57 IHC test, and is fasting required?
Quick Answer: No fasting or special preparation is needed. The test is performed on archival tissue from a previous biopsy or surgical procedure.
Your physician will submit the existing FFPE block or biopsy slide to our laboratory. You do not need to stop medications or alter your daily routine. Please ensure the accompanying histopathology report, exact biopsy site, and clinical history are provided with the specimen for accurate interpretation.
3. How reliable is the P57 IHC result, and will it guide my treatment plan?
Quick Answer: The test achieves 99.9% diagnostic sensitivity under ISO 9001:2015 accreditation when interpreted by an experienced pathologist.
A negative p57 result in a morphologically abnormal specimen confirms complete mole, which may necessitate chemotherapy if hCG levels fail to regress. However, the result is not a standalone diagnosis; it must be integrated with serial ฮฒ-hCG values, pelvic ultrasound, and clinical examination by your oncologist to formulate a personalised treatment and surveillance plan.
UAE Regulatory & Data Privacy Adherence
- Data Protection: All patient information is processed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Governance: Laboratory operations adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety & Consent: Tissue collection and testing procedures follow the standards set by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Quality Certification: The laboratory operates under ISO 9001:2015 accreditation with full DHA facility licensing.
Clinical & Logistical Metadata
| Test Name | P57 Immunohistochemistry (IHC) Test |
| Price (AED) | 450 AED |
| Turnaround Time | 5โ7 days from FFPE block receipt |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block / Biopsy Slide |
| Methodology Used | Immunohistochemistry (IHC) with monoclonal p57 antibody on FFPE tissue sections |
| ICD-10-CM Code | O01.9, O01.0, O01.1 |
| LOINC Code | 44669-0 |
| DHA Facility License & Address | DHA Facility License Number: 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab: DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians